Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective

Yuben Moodley, T.J. Corte, L. Richeldi, T.E. King

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

© 2015 Asian Pacific Society of Respirology. Idiopathic pulmonary fibrosis (IPF) is an incurable condition that is characterized by progressive pulmonary fibrosis, architectural distortion of the lung and loss of gas exchange units. Until recently, there was no effective treatment for this condition. However, there were two landmark trials published earlier this year, which have changed the management of this condition. Pirfenidone (Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis trial) and nintedanib (Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis-1 and -2 trials) have both demonstrated positive outcomes in patients with IPF. In this perspective, we critically discuss the role of these agents in IPF and in the broader pulmonary fibrosis population.
Original languageEnglish
Pages (from-to)389-394
JournalRespirology
Volume20
Issue number3
DOIs
Publication statusPublished - 2015

Fingerprint Dive into the research topics of 'Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective'. Together they form a unique fingerprint.

Cite this